GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (XTER:41O) » Definitions » Policy Acquisition Expense

Outlook Therapeutics (XTER:41O) Policy Acquisition Expense


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Outlook Therapeutics (XTER:41O) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.